Latest Ratios: P/E Ratio 135.4x · EV/EBITDA N/A · ROE 1.0%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $120M | $112M | $85M |
| Enterprise Value | $119M | $112M | $84M |
| P/E Ratio → | 135.38 | 162.88 | 33.93 |
| P/S Ratio | — | — | — |
| P/B Ratio | 1.07 | 1.29 | 0.99 |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | 43.89 |
| EV / EBIT | — | — | 43.89 |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 1.0% | 1.0% | 2.2% |
| ROA | 0.9% | 0.9% | 2.1% |
| ROIC | -2.6% | -2.6% | — |
| ROCE | -3.3% | -3.3% | -0.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | — | — | — |
| Debt / EBITDA | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.01 |
| Net Debt / EBITDA | — | — | -0.59 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($865031) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 0.40 | 0.40 | 5.90 |
| Quick Ratio | 0.40 | 0.40 | 5.90 |
| Cash Ratio | 0.38 | 0.38 | 5.36 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 0.7% | 0.6% | 2.9% |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | — | — |
| Shares Outstanding | — | $9M | $8M |
Business combination execution risk
As reported in financial statements, PCSC trades at a P/E of 136.62, a figure that appears largely disconnected from fundamental performance and instead reflects the market's speculative pricing of the sponsor's ability to identify and secure a high-quality biotechnology target within the remaining search window.
The elevated P/E ratio is an artifact of minimal earnings volatility rather than a reflection of growth prospects, as the company currently lacks operational revenue. Investors should monitor the P/B ratio of 1.08, which suggests the market is pricing the shares near the liquidation value of the trust account, leaving little room for error should the merger process face regulatory or market-driven delays.
Based on PCSC's reported figures, the ROIC has trended into negative territory, reaching -0.7% in 2026Q1, which illustrates the inevitable decay of invested capital as the entity incurs fixed administrative and compliance costs without generating any offsetting returns from operational activities or business combinations.
The negative return profile is structural for a pre-combination SPAC and highlights the inefficiency of holding capital in a shell vehicle over extended periods. This trend warrants further investigation into whether the sponsor's vetting process can eventually generate returns that exceed the current rate of capital depletion, or if the delay will continue to erode shareholder value.
According to recent SEC filings, PCSC's current ratio has plummeted from 50.57 in 2024Q2 to a precarious 0.23 by 2026Q1, indicating that the company's immediate liquidity buffer is no longer sufficient to cover its short-term liabilities as the search for a target continues to drain cash.
The sharp decline in the current ratio suggests that the company is increasingly reliant on the trust account or external financing to meet its ongoing obligations. This liquidity profile appears vulnerable, and investors should monitor whether the company can maintain sufficient working capital to sustain operations until a definitive merger agreement is reached.
Data from the financial statements indicates that the P/E ratio is the most commonly misapplied metric for PCSC, as it obscures the reality that the company is a pre-revenue shell entity where earnings are non-representative of future operational potential or long-term value creation.
Applying standard valuation multiples to a SPAC before a business combination is fundamentally flawed because it ignores the binary nature of the company's future. Instead of P/E, analysts should focus on the redemption rate and the quality of the PIPE commitment, as these metrics provide a more accurate assessment of the market's confidence in the sponsor's ability to execute a successful deal.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PCSC stock.
Perceptive Capital Solutions Corp Class A Ordinary Shares's current P/E ratio is 135.4x. The historical average is 98.4x. This places it at the 50th percentile of its historical range.
Perceptive Capital Solutions Corp Class A Ordinary Shares's return on equity (ROE) is 1.0%. The historical average is 1.6%.
Based on historical data, Perceptive Capital Solutions Corp Class A Ordinary Shares is trading at a P/E of 135.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.